Rick Cavalieri

Made in America. Banned in America. Braelyn's scans are clear thanks to an American treatment, one she has to fly to the UK to get. In Clemson, she told President Trump her story. No American should need a passport to get an American treatment. #RightToTry

$NWBO #DCVax #Glioblastoma #FDA #Stroke 𝗜𝗳 𝟮𝟲% 𝗜𝘀 𝗡𝗲𝘄𝘀, 𝗪𝗵𝗮𝘁 𝗜𝘀 𝟲𝟴%? On November 9, FDA approved Sunharbo (asundexian), a pill that lowers the risk of a second stroke by 26%. It was news, and it should be. Now look at a number in brain cancer that is not getting the attention it deserves. 💊 𝗧𝗛𝗘 𝗡𝗨𝗠𝗕𝗘𝗥 𝗧𝗛𝗔𝗧 𝗠𝗔𝗗𝗘 𝗡𝗘𝗪𝗦 OCEANIC-STROKE. 12,327 patients. Recurrent stroke: 6.2% vs 8.4%. Hazard ratio 0.74. Risk reduction 26%. In absolute terms: 2.2 points. About 45 people take the pill to prevent one stroke. The endpoint was stroke, not death. The trade-off: major bleeding 1.9% vs 1.7% overall, higher over age 75 and in the first 90 days, plus more gastrointestinal bleeding. 🧠 𝗧𝗛𝗘 𝗡𝗨𝗠𝗕𝗘𝗥 𝗧𝗛𝗔𝗧 𝗦𝗛𝗢𝗨𝗟𝗗 Recurrent glioblastoma kills most patients within a year of relapse. UCLA's phase 1 trial combined ATL-DC, a vaccine built from the patient's own dendritic cells and the patient's own tumor (the same class as DCVax-L), with poly-ICLC and Keytruda (pembrolizumab). 35 IDH wild type patients. Reported at EANO 2026. Keytruda before surgery and alongside the vaccine: median survival 271 days. Vaccine first, then Keytruda: 555 days. Hazard ratio for death 0.32, p<0.0006. The endpoint was survival. Same three drugs. Same disease. Put the vaccine first and the risk of death falls 68%. Survival doubles. 🔬 𝗪𝗛𝗬 𝗧𝗛𝗘 𝗢𝗥𝗗𝗘𝗥 𝗠𝗔𝗧𝗧𝗘𝗥𝗦 Checkpoint inhibitors failed three phase 3 trials in glioblastoma. UCLA's result suggests what was missing: an immune response built first. Vaccine first: more T cells in the tumor, more interferon and granzyme B. Keytruda first: chronic inflammatory responses in tumor and blood, and half the survival. 🛡️ 𝗧𝗛𝗘 𝗦𝗔𝗙𝗘𝗧𝗬 The vaccine is the patient's own cells. It is not a blood thinner. It is not chemotherapy. DCVax-L phase 3: 2,151 doses. 5 serious adverse events judged possibly related, all grade 2 or 3. No death attributed to the vaccine. No autoimmune reactions. No cytokine storm. In recurrent glioblastoma, the danger is the disease. 📣 𝗧𝗛𝗘 𝗔𝗧𝗧𝗘𝗡𝗧𝗜𝗢𝗡 𝗜𝗧 𝗗𝗘𝗦𝗘𝗥𝗩𝗘𝗦 A 2.2 point drop in strokes is rightly news. A doubling of survival in one of the deadliest cancers known should be bigger news. UCLA presents the data at the SNO Annual Meeting on November 14. Every neuro-oncologist, every reporter who covers cancer and every funder of brain tumor research should be reading that abstract. A result this large deserves a trial large enough to confirm it. Patients with recurrent glioblastoma cannot wait for the field to notice.

Stephen Moore’s Post  Stephen Moore 4d Made in America. Banned in America. Let me tell you about a remarkable young woman named Braelyn. She was diagnosed with brain cancer at 16. Today she's 19, and her scans are clear. The treatment that got her there was invented by an American company, with American science and American ingenuity. Here's the outrage: Braelyn can't get it here. She has to travel to the UK for treatment. Think about that. We lead the world in medical innovation, and then we make our own citizens leave the country to benefit from it. The British are getting American breakthroughs that Americans can't. That isn't a free market. That's a regulatory roadblock, and it costs lives. President Trump understood this when he signed Right to Try in 2018. The idea was simple: if you're facing a life-threatening diagnosis, Washington shouldn't stand between you and a treatment that might save you. It was one of the best things he did in his first term. But Braelyn's story tells me the job isn't finished. The promise of Right to Try still isn't reaching the patients who need it most. When the President came to Clemson, South Carolina, for a rally near Braelyn's home, our team made sure she was there. Braelyn got her moment with the President, and he heard her story. Now it's Washington's turn. Make Right to Try work the way it was meant to. Put American cancer vaccine breakthroughs in the NCI Cancer Vaccine Initiative. And stop exporting our breakthroughs while our patients wait. No American should need a passport to get an American treatment. Bring it home. Thank you to Braelyn and her family for their courage in sharing her story. #RightToTry #BringItHome #UnleashProsperity #DCvaxForBraelyn

All through Covid, we were told "trust the science! Trust the science!" Now it seems that it's "trust the science" unless it's a company forced to be on the OTC trading board by unscrupulous market makers. Does a share price under a dollar have anything to do with SCIENCE? Check out all the science and data that NWBO has with their dendritic cell platform! God forbid you get diagnosed with GBM. Would you prefer a treatment that has not shown any long term benefit from a $50/sh company over a company with a share price under $1 but has patients surviving 20 years??

Phenomenal!!!! Way to go, Braelyn and Amanda!! Patients need access now! My husband @mfhugo1 needs access now! Thank you Sharon Hodgson, Labor MP for demanding widespread access so this therapy can save even more lives.

🇬🇧❤️ WHAT AN INCREDIBLE WAY TO END AN EXTRAORDINARY WEEK IN LONDON! Today, Braelyn received her 5th DCVax treatment with the wonderful Professor Keyoumars Ashkan at King’s College Hospital! Prof. Ashkan was absolutely thrilled about the extraordinary week Braelyn has had in London. And apparently, word travels FAST! He already knew that Braelyn’s story had been shared in the House of Commons during Prime Minister’s Questions! 🇬🇧 But my favorite moment came when I mentioned Braelyn’s latest MRI, which showed NO EVIDENCE OF DISEASE. I had mailed him a hard copy and wanted to make sure he’d received it. His response? “I’VE SEEN IT! THE ENTIRE UK HAS SEEN IT!” 😂❤️ I just LOVE this man! We had sent him and his wonderful assistant our “Because Gray Matter Matters” t-shirts after our last visit, but looking at these pictures, I think I may have seriously overestimated Prof. Ashkan’s shirt size! 😂 This brilliant, compassionate neurosurgeon has played such an important role in helping Braelyn access DCVax-L, and we will forever be grateful for his dedication to patients battling brain cancer. From the halls of Parliament to another precious dose of Braelyn’s personalized cancer vaccine, what an unforgettable week! Thank you, Professor Ashkan, for everything you do for Braelyn and so many other patients. You are truly extraordinary! ❤️🙏 #DCVaxForBrarlyn #BrainCancer #BraelynsFight #DCvax

What an absolute honor to have been invited to sit in the Speaker’s VIP box. A huge Thank You to Sharon Hodgson, Labour MP for highlighting this very important issue affecting so many people in both of our countries, and beyond. We are grateful for the warm reception and the support of our “cousins” on the other side of the pond! #DcVaxForBraelyn @DrOzCMS

$NWBO #DCVaxForBraelyn $AZN $MRK 𝗔𝘀𝘁𝗿𝗮𝗭𝗲𝗻𝗲𝗰𝗮 𝗶𝘀 "𝗰𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗶𝗻𝗴" 𝗰𝗮𝗻𝗰𝗲𝗿 𝘃𝗮𝗰𝗰𝗶𝗻𝗲𝘀. 𝗧𝗵𝗲 𝗮𝗻𝘀𝘄𝗲𝗿 𝗶𝘀 𝗳𝗶𝘃𝗲 𝗺𝗶𝗹𝗲𝘀 𝗳𝗿𝗼𝗺 𝗣𝗮𝘀𝗰𝗮𝗹 𝗦𝗼𝗿𝗶𝗼𝘁'𝘀 𝗱𝗲𝘀𝗸. Bloomberg says questions remain over how broadly the technology will work. The technology, and the answer, are manufactured a fifteen-minute drive from AstraZeneca's front door. 𝗧𝗵𝗲 𝗴𝗲𝗼𝗴𝗿𝗮𝗽𝗵𝘆 
AstraZeneca's global HQ: 1 Francis Crick Avenue, Cambridge Biomedical Campus. Five miles south, at Sawston Business Park, Northwest Biotherapeutics owns an 88,000 square foot cell therapy plant holding one of the first commercial cell-therapy manufacturing licences the MHRA ever issued, HTA-licensed cryostorage built for millions of vials, and a closed, automated Grade C suite going in. Cambridgeshire has applied to the government to build a dedicated busway from Francis Crick Avenue to Sawston, ten to twelve minutes stop to stop. They are literally paving the road between the two. And in April AstraZeneca un-paused its £200m Cambridge expansion. It is not leaving the neighborhood. It is doubling down on it. 𝗧𝗵𝗲 𝗼𝗯𝗷𝗲𝗰𝘁𝗶𝗼𝗻𝘀, 𝗶𝗻 𝗔𝘀𝘁𝗿𝗮𝗭𝗲𝗻𝗲𝗰𝗮'𝘀 𝗼𝘄𝗻 𝘄𝗼𝗿𝗱𝘀 
Dave Fredrickson conceded other companies are better positioned to advance personalized cancer vaccines at pace. Correct. AstraZeneca did not grow its cell therapy franchise in-house. It bought it, deal by deal: TeneoTwo, Neogene, Gracell, EsoBiotec, Cellectis, Quell. The pattern is not subtle. Susan Galbraith: "cost and turnaround time will still mean that it's challenging to scale." That is an mRNA problem. A neoantigen vaccine needs tumor sequencing, an algorithm guessing which mutations matter, and a bespoke batch inside a four to six week window. Then it still has to find the patient's dendritic cells and hope they present it. #DCVax-L removes the bet. It loads the dendritic cells directly with whole tumor lysate, no sequencing, no guessing, the full antigen repertoire, and makes a patient's entire multi-year course in a single eight-day batch, frozen in single doses. Personalized once, off the shelf forever. Galbraith also wants proof beyond melanoma. Melanoma is the most immunogenic tumor there is. #Glioblastoma is about as cold as tumors get: mutation-poor, immune-privileged, behind the blood-brain barrier. DCVax-L's 331-patient Phase 3 was in glioblastoma and is published in JAMA Oncology. Anyone asking how broadly a vaccine can work should start with the one that worked where nothing works. 𝗙𝗿𝗲𝗱𝗿𝗶𝗰𝗸𝘀𝗼𝗻'𝘀 𝗼𝘄𝗻 𝘁𝗲𝘀𝘁: best in class, first, scale. A completed Phase 3. A marketing application sitting with the MHRA since December 2023, which the agency confirmed in July is progressing toward a first decision, the same regulator that licensed the Sawston plant. A facility designed for 300 staff at full build-out. Best, first, scale. Five miles away. 𝗧𝗵𝗲 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆 
Merck paired Keytruda with Moderna's vaccine and cut the risk of melanoma recurrence or death by 42%. AstraZeneca has Imfinzi and no vaccine. A checkpoint inhibitor can only release T cells that already exist. A dendritic cell vaccine is what creates them. Imfinzi needs a partner, and the partner is already licensed, already producing, and already in Cambridgeshire. Soriot told analysts "you'll hear more about this in the months and years to come." He could hear it before lunch. These are not competitors. They are neighbors, and the most obvious deal in oncology is a fifteen-minute drive. bloomberg.com/news/articles/…

Open your eyes people! Does this sound like a company that's expecting approval or rejection?

🚨🇺🇸 BRAELYN’S STORY JUST MADE FOX BUSINESS! 🇺🇸🚨 What an incredible moment for our family! Today on Varney & Co., Stuart Varney brought up Steve Moore’s recent Rasmussen Reports article about Braelyn and the barriers seriously ill Americans face in accessing promising experimental treatments! Steve shared Braelyn’s story and called out the FDA, saying it’s CRUEL to withhold promising investigational treatments from desperately ill patients. Varney agreed, arguing that patients facing terminal illnesses should have the freedom to accept the risks of experimental treatments without liability concerns preventing companies from providing them. Then Steve asked a powerful question: “Whatever happened to my body, my choice?” He also pointed out that President Trump supports Right to Try, yet significant barriers remain between patients and the treatments they desperately need. THIS is the conversation we’ve been fighting to bring into the national spotlight! Our 19-year-old daughter is attending college, and her latest MRI shows no evidence of cancer recurrence. Yet we still have to travel to ENGLAND for her ongoing DCVax-L treatments—developed right here in AMERICA! We are so incredibly grateful to Steve Moore and Stuart Varney for bringing attention to Braelyn’s story and, more importantly, to the countless patients who deserve a fighting chance. Patients facing life-threatening illnesses shouldn’t have to fight their own government for the opportunity to fight for their lives. PLEASE WATCH AND SHARE! ❤️🙏 @realDonaldTrump @DrOzCMS @SecKennedy #DCVaxForBraelyn #RightToTry #DCVax #BraelynsFight $NWBO

$NWBO Did we just find the missing link on a RELATIONSHIP between NHSBT and MHRA? If so, the news on NHSBT manufacturing support might have stemmed from the MHRA regulatory process. Thanks to red_right_hand on Ihub for finding this. gov.uk/government/publicatio… There is a documented working relationship between NHSBT and MHRA. In July 2026, they jointly announced a regulatory decision on plasma medicines, bringing together MHRA’s safety assessment and NHSBT’s plans to strengthen supplies. This demonstrates direct cooperation over getting treatments to patients. MHRA also has a formal system for sharing estimated decision dates with NHS England and other named health organisations, with the applicant’s consent. The purpose is straightforward: help the NHS prepare services ahead of a decision so patients can access newly approved treatments sooner. NHSBT’s government framework reinforces this approach, specifically identifying collaboration with partners to develop and expand NHS services as a strategic objective. For NWBO, this makes NHSBT’s reported involvement in DCVax-L cell collection and processing at Leeds and Oxford, alongside discussions about expansion, particularly encouraging. These activities address practical requirements for delivering a personalised treatment to more patients. The remaining gap is whether these connections were used to share information specifically about DCVax-L. NHSBT sits outside the information-sharing scheme’s named recipients, and onward disclosure is restricted. That requires separate evidence. A bullish interpretation is that DCVax-L is gaining practical NHS support within a health system designed to coordinate preparation around regulatory decisions. That strengthens the commercial-readiness story and makes coordinated planning plausible. Confirmation of a favourable CHM outcome remains the decisive missing piece. Sources 1. MHRA and NHSBT joint announcement, July 2026 Demonstrates direct cooperation between MHRA and NHSBT concerning regulatory decisions and medicine supplies. GOV.UK - MHRA safety review gives UK plasma donations go-ahead⁠ 2. MHRA Operational Information Sharing Guidance, January 2026 Establishes how MHRA shares anticipated regulatory decision dates with NHS England and other designated health organisations to support preparations for patient access. GOV.UK - Operational Information Sharing Guidance⁠ 3. DHSC and NHSBT Framework Agreement, September 2025 Documents NHSBT’s formal relationship with the Department of Health and Social Care and its responsibilities for collaboration, service development and operational planning. GOV.UK - DHSC and NHSBT Framework Agreement⁠ 4. NHSBT Chief Executive’s Board Report, July 21, 2026 Documents cooperation between NHSBT, NHS England and DHSC concerning medicines supply and operational capacity. NHSBT - Chief Executive’s Public Board Report (PDF)⁠ 5. NHSBT announcement on DCVax-L, October 2026 Confirms NHSBT’s involvement in immune-cell collection and processing supporting DCVax-L production, initially involving Leeds and Oxford, with further expansion being explored. NHSBT - Specialist Therapeutic Apheresis and Cell Processing Support for DCVax-L⁠ 6. Northwest Biotherapeutics announcement, October 8, 2026 Provides NWBO’s account of the NHSBT collaboration and the preceding months of joint preparation. NWBO - Collaboration with NHS Blood and Transplant⁠ Important distinction: These sources document institutional coordination and DCVax-L manufacturing preparations.

LeBron made $1.4 billion in our country and this is how he shows his gratitude

Seconds before the national anthem begins, players from both WNBA Finals teams jog off the court. And for the third straight game, they don't return until the song is over. The Atlanta Dream and Golden State Valkyries repeat the routine Wednesday night at State Farm Arena, despite league rules requiring players, coaches and trainers to stand in line during the anthem. @Outkick reports that the WNBA, both teams and the NBA have yet to answer questions about the repeated absences or whether any disciplinary action is being considered. See what else OutKick observed during the Game 3 anthem: foxnews.com/outkick-sports/a…

❤️ IT’S OFFICIAL! WE’RE MEETING PRESIDENT TRUMP TOMORROW! 🇺🇸 Braelyn and I have been invited to attend tomorrow’s rally for Darline Graham in Clemson! We’ll be seated in the VIP section AND have the opportunity to meet President Trump in the “click line”! Ben is cutting his work trip short, and we’re hoping he’ll make it home in time to join us! We’ll have only seconds with the President, but I intend to make every one of them count. I’ll also be bringing information for him and his staff about Braelyn, DCVax-L, and the barriers American patients face trying to access promising treatments developed right here in the United States. This is an extraordinary opportunity, but we’re hoping it can become something even bigger. PLEASE HELP US GET THE ATTENTION OF THE WHITE HOUSE PRESS TEAM! 🙏 We would love the opportunity for a longer conversation with President Trump or his administration about how we can make these treatments accessible to American patients. Please SHARE, REPOST, and TAG anyone who might help get Braelyn’s story in front of the right people! Three years ago, Braelyn was given just months to live. Today she’s 19, attending college, and her latest MRI shows NO EVIDENCE OF DISEASE RECURRENCE! Her story deserves to be heard. And so do the stories of countless other patients fighting for access to promising treatments. @realDonaldTrump @DrOzCMS @WhiteHouse #DCVaxForBraelyn #DCVax #PresidentTrump

Once again, both WNBA Finals teams leave the court as soon as the national anthem starts and return almost the second it ends.

$NWBO A video letter to President @realDonaldTrump @HollensbeBrae is the young woman whose Glioblastoma story you recently shared with @DrOzCMS. Braelyn and her parents live ten minutes from Wednesday’s campaign stop in Clemson and would like to meet you. “Today she’s 19 years old, attending college, living her life - and her latest MRI shows no evidence of disease.” Braelyn receives DCVax-L, a promising personalized cancer vaccine developed by American scientists (@NorthwestBio). But she can’t get it in the U.S. Her family has to travel back and forth to England for compassionate use. “For three years I fought to save my daughter‘s life and along the way I’ve discovered just how difficult it is for American patients to access promising investigational treatments - even when those treatments were developed right here in their own country. We need to ask some very serious questions about the barriers facing smaller biotechnology companies, the influence of the pharmaceutical industry, and why patients are left waiting while promising treatments navigate years of regulatory hurdles… …You signed right-to-try into law and I tremendously appreciate what that legislation was intended to accomplish, but I’ve learned firsthand that having the right to request a treatment doesn’t necessarily mean a patient can actually obtain it… An American family shouldn’t have to cross an ocean to receive a promising cancer treatment developed by American scientists…” — @HollensbeAmanda